Renal hyperfiltration patterns separate mortality risk from cardiovascular risk
A nationwide Korean cohort of 1,022,062 adults shows that renal hyperfiltration is not a static laboratory curiosity. Its clinical meaning changes when the excess filtration persists, disappears, or newly appears over time, and those transition patterns mapped to different risks for death and cardiovascular events.
The study defined renal hyperfiltration as an estimated glomerular filtration rate above the 95th percentile after multiple adjustments. Participants underwent consecutive health screening examinations between 2012 and 2015 and were then grouped by whether hyperfiltration was absent, newly developed, disappeared, or persistent. That design matters because a single elevated eGFR can reflect a transient physiologic state, while repeated hyperfiltration suggests a more durable renal-hemodynamic abnormality.
Persistent hyperfiltration carried the clearest adverse signal. Compared with RHF-free individuals, the persistent group had the highest adjusted risk of mortality, with a hazard ratio of 1.61, and the highest cardiovascular risk, with a hazard ratio of 1.39. Those two figures are not interchangeable. Mortality and cardiovascular events tracked different transition patterns, pointing to distinct biologic pathways rather than one uniform risk state.
A dynamic kidney phenotype with different downstream consequences
The kidney may be telling two separate stories at once. Hyperfiltration can arise from glomerular hypertension, altered renal autoregulation, or early metabolic injury, and those mechanisms can affect the vasculature and overall survival on different timelines.
Mortality risk increased across all RHF transition patterns except the RHF-free group, regardless of exposure duration or the slope of hyperfiltration excess. In other words, any pattern of hyperfiltration history seemed to carry a mortality penalty once the cohort moved away from a consistently normal filtration state. That broad association suggests that RHF may function as a marker of systemic vulnerability, not only a kidney-specific abnormality.
Cardiovascular risk behaved differently. The excess CV risk was concentrated in the RHF-disappeared pattern and the RHF-persistent pattern, while RHF-development did not show the same cardiovascular signal. The pattern is clinically striking: a person whose hyperfiltration resolves does not simply revert to baseline cardiovascular neutrality, particularly if the period of excess filtration lasted longer or if the degree of excess filtration declined over time.
One sentence captures the split plainly: mortality rose across every non-free transition pattern, but cardiovascular events did not.
Why disappearance did not erase cardiovascular risk
The most counterintuitive finding lies in the group whose hyperfiltration disappeared. CV risk increased primarily in this subgroup, especially with longer RHF exposure and declining hyperfiltration excess. That suggests the kidneys may record cumulative injury before routine screening normalizes the eGFR value.
A disappearing hyperfiltration pattern may reflect partial recovery of glomerular hemodynamics rather than true biologic reset. If earlier hyperfiltration caused endothelial stress, intraglomerular pressure injury, or broader metabolic disturbance, the vascular consequences could linger even after the filtration marker retreats toward the reference range. The data do not measure mechanism directly, but the outcome pattern fits a model in which renal recovery and vascular recovery do not occur on the same schedule.
RHF-development did not show the same cardiovascular association. Newly appearing hyperfiltration may represent an earlier phase of disease, a shorter exposure window, or a phenotype that has not yet translated into overt cardiovascular damage. The study does not give a direct answer on which explanation is correct, but the asymmetry between development and disappearance argues against treating all hyperfiltration transitions as equivalent.
Screening eGFR may need to be read as a trajectory, not a single value
This cohort study places a practical burden on routine screening programs. A one-time elevated eGFR can no longer be read in isolation when repeated measures are available. The direction of change, the duration of exposure, and the persistence of excess filtration all appear to matter.
For nephrology and primary care, the findings support serial interpretation of renal function rather than a snapshot approach. A patient whose eGFR falls from hyperfiltration into the normal range may still warrant closer cardiovascular attention, especially if the hyperfiltration phase was prolonged or marked by a large excess over the threshold. Conversely, persistent RHF appears to identify a higher-risk group for both death and cardiovascular events, making it the most concerning phenotype in the cohort.
The study also reinforces an important bedside point: preserved or even high eGFR does not always mean low risk. Hyperfiltration can sit at the beginning of a pathophysiologic sequence that eventually leads to vascular injury, kidney damage, or both. In that setting, a “good” creatinine-based estimate may conceal an abnormal hemodynamic state rather than reassure.
What the cohort can and cannot tell clinicians
The dataset is large and the associations are consistent, but the design remains observational. It identifies risk stratification patterns, not treatment effects. No intervention was tested, and the abstract does not provide granular information on comorbidities, medication use, albuminuria, or causes of death beyond the broad mortality outcome.
Still, the internal contrast between persistent, disappeared, and newly developed hyperfiltration is difficult to ignore. Persistent RHF marked the highest combined risk burden. Disappeared RHF still carried cardiovascular risk, especially with longer exposure. Mortality increased across every transition pattern outside the RHF-free group.
That combination makes renal hyperfiltration less useful as a one-time label and more useful as a dynamic biomarker. Serial eGFR trajectories may help clinicians identify who needs tighter cardiovascular surveillance, even when kidney filtration appears to normalize on paper.
The unresolved question is not whether RHF matters, but how much of its risk is reversible once the eGFR trajectory changes. This cohort shows that disappearance does not necessarily reset cardiovascular risk, and persistent hyperfiltration remains the most ominous pattern.